Compare ARK Genomic Revolution ETF (ARKG) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Huntington Ingalls Industries Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.59, while Huntington Ingalls Industries Inc trades at $286.28 (market cap $11.27B). The key difference: Huntington Ingalls Industries Inc pays a 1.93% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Huntington Ingalls Industries Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | HII | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $453.73 |
52-Week Low | $23.09 | $252.93 |
Market Cap | — | $11.27B |
Enterprise Value | — | $13.99B |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
HII trades at $286.09, down 0.04% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows stable profitability with a 4.71% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights ongoing naval contracts and shipbuilding milestones, supporting revenue visibility from its $54 billion backlog.
The stock presents a value opportunity with a P/E of 18.59 and P/S of 0.88 below industry averages, alongside a 44% analyst buy rating and a $384.50 price target implying significant upside. Risks include defense budget dependency and execution challenges, but strong cash flow and dividend payments bolster investor appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
